WuXi AppTec Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From WuXi AppTec Inc.
Senate Work On Biosecurity Issues Continues Even As House Is Current Focus Of Legislative Activity
US FDA Principal Deputy Commissioner Namandjé Bumpus recently attended a biotech-themed roundtable with the Senate Select Committee on Intelligence and national security officials as Congress’ pulls the FDA into its worries about Chinese influence of the pharma industry.
BIOSECURE Act Update Offers Biotech Companies Eight Years to Divest Contracts With Firms Of ‘Concern’
But that clock is already ticking as the House Oversight and Accountability Committee prepares to mark-up the bill and a likely reconciliation effort with the Senate looming.
A Snapshot of Updates In The APAC Region
US-China tensions, the increasing importance of Singapore as a doorway to the Asia-Pacific region, growing AI innovation in South Korea and a changing clinical trials landscape in Japan are just some of the recent developments in APAC.
Risks For Pharma Industry Remain As BIO Shifts Course On BIOSECURE Act
Trade group’s break from WuXi Apptec allows BIO to reset its lobbying approach under its new CEO but doesn’t negate the business and supply chain disruptions that biopharma would feel from the proposed legislation.
Company Information
- Industry
- Biotechnology
- Contract Research, Toxicology Testing-CRO
- Medical Devices
- Pharmaceuticals
- Services
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice